Work

Abstract B015: A Phase 2 Study of Ateganosine (THIO) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced NSCLC Resistant to Prior ICI and Chemotherapy: THIO-101 Trial in Progress

Year: 2025

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-25-b015

Authors: Veronika Muller, Tomasz Jankowski, Mariola Kowal-Rosinska, Laszlo Urban, Tibor Csoszi, Tunde Nagy, Rodryg Ramlau, Maria Cholakova, Nataliya Chilingirova, Szabolcs Soter, Krassimir Koynov, Marek Kotlarski, Ilgen Mender, Romina Girotti, Marcel Mitsunaga, Oleg Tudos, Matthew Failor, Vlad Vitoc, Sergei Gryaznov, Victor Zaporojan

Institutions: Semmelweis University, Eötvös Loránd University, Poznan University of Medical Sciences, Országos Korányi Tbc és Pulmonológiai Intézet

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415444384

Cites:

Cited by:

Related to: